Domestic benchmark indices erased the day's gains on Wednesday as the final hour of the trading session witnessed heavy selling in financial stocks and RIL. Sensex closed nearly flat at 36,051.81, registering a mere increase by 18.75 points or 0.05 per cent compared to its previous close. Nifty ended today's session at 10,618.20, up by 0.10 per cent or 10.85 points.

Majesco provides technology, expertise and leadership by helping insurers modernise and innovate in order to build a future of their business as well as insurance at scale and speed.  

The shares of Salasar Techno Engineering were trading in green after the company declared after trading hours on Tuesday that it has received an order for the supply of 189 telecom towers to American Tower Corporation (ATC) Nigeria for a total consideration of US$ 2.43 million (Rs 18.50 crore at current exchange rate).

As a part of this integrated business-to-business (B2B) alliance, Airtel is set to offer ‘Airtel BlueJeans’, an enterprise-grade video conferencing solution to enterprise customers in India.

The market opened in the green on July 15, 2020. 

The market opened in the green on July 15, 2020, overall volumes in futures & options currently stand at 2,49,51,077 crore contracts with a turnover of Rs. 15,10,278.71 crore.

The market opened in the green on July 15, 2020, overall volumes in futures & options currently stand at 2,49,51,077 crore contracts with a turnover of Rs. 15,10,278.71 crore.

India Ratings & Research (Ind-Ra) in its latest report has pointed out that the private sector’s capital expenditure is set to contract by 20-26 per cent in the ongoing financial year, owing to COVID-19 pandemic-led business disruptions

Dilip Buildcon announced that its joint venture was declared as the L-1 bidder for the tender floated by National Highways Authority of India (NHAI) for a highway project in Jharkhand and Bihar.

Zydus Cadila has commenced the adaptive phase I/II human clinical trials of its plasmid DNA vaccine, ZyCoV-D with the first human dosing. The safety, tolerability and immunogenicity of the vaccine will be assessed later on.